High levels of loss at the 17p telomere suggest the close proximity of a tumour suppressor. by White, G. R. et al.
British Journal of Cancer (1996) 74, 863-870
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 M
High levels of loss at the 17p telomere suggest the close proximity of a
tumour suppressor
GRM White', M Stack2, M Santiba'niez-KoreP, DS Liscia4, T Venesio4, J-C Wang5, C Helms5,
H Donis-Keller5, DC Betticher6, HJ Altermatt6, PR Hoban' and J Heighwayl
'CRC Department of Cancer Genetics, Paterson Institutefor Cancer Research, Christie Hospital (NHS) Trust, Wilmslow Road,
Manchester M20 4BX, UK; 2Department ofMedicine, Tenovus Building, University of Wales College ofMedicine, Cardiff, CF31
4XX, UK; 3Genome and Gene Evolution Group, MRC Clinical Sciences Centre, Postgraduate Medical School, Hammersmith
Hospital, Du Cane Road, London W12 ONN, UK; 4Servizio di Anatomia Patologica, Ospedale San Giovanni Antica Sede,
Dipartimento oncologico USL-1, via Cavour 31, 10123 Turin, Italy; 5Departments ofGenetics, Psychiatry and Surgery, Washington
University School ofMedicine, St Louis, Missouri 63110, USA and 6University Hospital ofBerne, Berne, Switzerland.
Summary High levels of loss of distal markers on 17pl3.3 in breast cancer suggested the presence within the
region of at least one tumour-suppressor gene. Here we describe the derivation of two biallelic polymorphisms
from the 17p telomeric yeast artificial chromosome (YAC) TYAC98. Polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) and multiplex PCR analysis demonstrated that the high level of
allelic imbalance observed in breast tumours represented loss of constitutional heterozygosity (LOH) and that
this LOH extended to the telomere. Lung carcinoma (but not Wilms' tumour)-derived DNA again revealed a
high level of loss of subtelomeric 17p sequences. Telomeric microsatellite polymorphisms from other
chromosome arms did not show such elevated loss in either tumour type. This suggested that the 17p loss
observed did not reflect a general telomeric instability and provided further evidence for the presence of a
breast cancer tumour-suppressor gene in the distal region of 17pl3.3.
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A highly complex pattern of loss of constitutional hetero-
zygosity (LOH) is observed in human malignancy. Most
current models of carcinogenesis assume clonal development
of the tumour, with successive genetic lesions conferring an
increased proliferative advantage. At the simplest level
therefore, every LOH event observed should reflect some
such advantage to the malignant cell. However, the situation
is likely to be more complicated. If two lesions occur within
the same cell at the same time, one conferring a growth
advantage the other being silent, then selective pressure will
favour the first but both will be present in the resulting clone.
This situation may result in confusion over which genomic
alterations, in any given tumour, have contributed to the
malignant phenotype. It is assumed that if an LOH event
occurs at high frequency (>20% of tumours of a particular
type) then it is likely to reflect loss of wild-type function of a
tumour-suppressor gene encoded within the region of loss.
An individual with a germline mutation in a tumour-
suppressor gene might display an increased risk of malignant
disease. The individual may pass on this mutation to children
who will incur a similar disease risk. Analysis of subsequent
tumours often shows that the corresponding normal allele has
been deleted in an LOH event. In the case of familial disease,
where a genetic linkage or cytogenetic abnormality has
helped to target the disease locus, a number of novel
tumour-suppressor genes have been identified, including
WTJ (Call et al., 1990), RBI (Weinberg, 1990), BRCAJ
(Miki et al., 1994) and APC (Joslyn et al., 1991). Conversely,
LOH analysis alone has been a historically less successful
route to suppressor identification. However, given the
imminent localisation of the majority of human genes, the
best application of such work might be to provide evidence
for the involvement of particular regions in the development
of disease. Genes sublocalised to these areas can be quickly
examined for a role in malignancy.
Loss of function of the p53 protein, located within
17pl3.1, is an important event in the initiation/progression
of many human tumours (Baker et al., 1989; Prosser et al.,
1990; Mitsudomi et al., 1992). However, LOH studies in
breast cancer have suggested the presence of another tumour-
suppressor gene mapped to chromosomal region 17pl3.3
(Coles et al., 1990; Cornelis et al., 1994; Merlo et al., 1994).
Our recent work revealed a complex pattern of LOH in this
region in breast tumours (Stack et al., 1995). The highest loss
(60-70%), and therefore perhaps the most likely site of the
putative suppressor gene, was defined by the three most distal
17p markers, D17S926, D17S695 and D17S849, which were
mapped and ordered by fluorescence in situ hybridisation
(FISH) to a position near the telomere (for physical map of
markers, see Stack et al., 1995). Although some tumours
showed loss across the whole region studied, many showed
retention of more proximal markers, excluding a direct
involvement of TP53. However, in order to define the extent
of the deletions observed and to investigate involvement of
the telomere, more distal markers were required.
Yeast artificial chromosomes (YACs), encoding inserts
derived from a number of human telomeres, including 17p,
were isolated by constructing and screening a single arm,
vector library with a TTAGGG 40mer probe (Vocero Akbani
et al., 1996). Encoded microsatellite repeat markers were
subsequently identified from many telomeres. However, none
were isolated from the 17p-encoding YAC. An alternative
strategy was therefore employed and the restriction fragment
length polymorphism (RFLP) systems derived were used to
investigate LOH in several tumour types.
Materials and methods
Patient information and DNA extraction
Paired primary breast tumours and normal samples were
obtained from patients at the S. Giovanni Vecchio Hospital,
Turin, Italy as previously outlined (Merlo et al., 1994).
Further breast samples and corresponding normals (periph-
eral blood) were obtained serially from the Withington
Hospital, Manchester, UK. Lung samples were obtained
from the University Hospital of Berne, Switzerland, from
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patients with resectable staged, non-small-cell lung cancer.
The panel included squamous cell carcinomas (L2, L26, L27,
L28, L61, L71, L72, L74, L76, L80 and L100), adenocarci-
nomas (L35, L69, L77 and L91), large-cell carcinoma (L95),
carcinoid (L78) and undifferentiated, non-small-cell (L86)
samples. In addition to the tumour, normal lung tissue,
distant from the tumour site, was resected. Wilms' tumour
samples (and peripheral blood controls) were obtained from
patients of the Royal Manchester Children's Hospital,
Pendlebury, Manchester. Normal DNA for 17TEL allele
frequency determinations were derived from samples (blood/
normal lung) from the breast/lung cancer series of patients.
In all cases DNA was extracted using standard protocols
(Sambrook et al., 1989). Approximately 100 ng was used for
subsequent polymerase chain reactions (PCRs).
PCR conditions
Standard PCR reactions were performed in 25 ,ul volumes
containing a final concentration of 1 x PCR buffer, 100 giM of
each dNTP (Promega), 1 gM of each primer and 1 U of Taq
DNA polymerase. For the HhaI polymorphism Dynazyme
buffer and polymerase supplied by Flowgen was used. All
other PCRs were conducted using buffer and polymerase
supplied by either Promega or Boehringer Mannheim.
Amplification was performed in an automated thermal
cycler (Techne) with a 5 min 97°C denaturation step, then
polymerase addition, followed by 35 cycles of 94°C
denaturation (96°C for Dynazyme) for 1 min, 55°C (biallelic
polymorphisms and vectorette libraries) or 60°C (micro-
satellites) annealing for 1 min, and extension at 72°C for
1 min. The last cycle was followed by a final extension at
72°C for 10 min.
Vectorette libraries
Vectorette libraries (Riley et al., 1990) were constructed using
DNA from TYAC98 and digested with several different
blunt-end cutting restriction enzymes [AluI, HaeIII, HincII,
RsaI (all Promega) and Nla IV (New England Biolabs)] and
ligated to blunt-end vectorette units (Cambridge Research
Biochemicals). Restriction digests of 1 jug of TYAC98 DNA
were in 50 il for 2 h at 37°C with 10 U of enzyme (3 U for
NlaIV) and manufacturers' 1 x buffer. This was followed by
enzyme inactivation (15 min at 65°C). Each digest (5 ,ul) was
ligated with T4 DNA ligase (Promega) in 25 1l for 2 h at
37°C with 1.5 pmol of blunt-ended double-stranded vector-
ette unit and 1 x ligase buffer (Promega). These libraries were
then diluted to 250 ,ul and 1 pl of each library used in PCRs
with 1 ,UM universal vectorette primer (Cambridge Research
Biochemicals) and 1 guM of the specific primer under study.
Product yield and specificity was improved by dilution of the
PCR product 1: 100 and reamplification of 1 1.d (20 cycles),
using the specific primer with a vectorette-nested primer
(Cambridge Research Biochemicals).
Sequencing
The vectorette-nested primer used to screen the vectorette
libraries was biotinylated allowing direct sequencing (Hult-
man et al., 1989) using Dynabeads M-280 (Dynal). After
90,l of biotinylated PCR product was bound and strand
separated the beads were resuspended in 7 ,ul of distilled
water. This template and 200 ng of specific primer were used
in a conventional dideoxy chain termination sequencing
reaction (Sequenase v2.0, USB).
Genotyping and mapping
A total of 23 CEPH families were found to have parents
heterozygous for the DdeI RFLP. All available members were
genotyped yielding 255 informative meioses. Genotypes were
entered into a Macintosh Hypercard application which was
used to prepare the input genotype file for the linkage
analysis program. Data were transferred to a SPARCstation
(Sun Microsystems) for processing. The 17p genotype data
were merged with the chromosome 17 marker data in the
CEPH database (version 7.1) for the linkage mapping. The
computer program CRI-MAP version 2.4 (1989) from P
Green (unpublished) was used for two-point and multipoint
mapping. The position of 17TEL(DdeI) relative to 17p
markers was determined (1000: 1 odds).
LOH analysis
For LOH studies tumour and normal products were run in
adjacent gel tracks and the relative allele intensities compared
visually. For biallelic 10 tl ofPCR product was digested with
10 U restriction enzyme in a 40 1.l reaction with
1 x manufacturer's buffer at 37°C for 3 h and the product
run on a 2.5% ethidium bromide-stained SEAKEM GTG
(FMC) agarose gel. Microsatellite analysis was carried out as
previously described (Orphanus et al., 1993). Primer
sequences for the telomeric microsatellite repeats studied are
shown below:
2p (sFJS14)
6q (sAVA3)
Ilp (D1lS2071)
14q (D14S826)
16q (D16S303)
18q (D18S497)
(=D18S70)
22q (sJCW16)
Xq (DXS1108)
5'-CTCCACTTAAGCTTGGTTTACA 119-135 bp
5'-CCCTAAAAGCCTCACTACATG (Vocero Akbani
et al., 1996)
5'-GGCTAATAAATGCTTAGAGCC 100-116 bp
5'-GGGCTTAGTTGTTTTCCATTAG (Vocero Akbani
et al., 1996)
5'-AGGGCAATGAGGACATGAAC 168 -202 bp
5'-ATGTGGCTGGTCCACCTG (Browne et al.,
1995)
5'-TGCTGTTGGACTCAGGTAGCTA 145 -161 bp
5'-TCTCTAAAGCTACTATAACCCAG (Pandit et al.,
1995)
5'-CAACAAGAGCGAAACTCGGTCTCAA 101-115 bp
5'- (Shen et al., 1994)
GATCAGTGCTCGTTTTTTTTGGTTTGG
5'-ATTGCCATTCAAGGCTGAAC 118-144 bp
5'-GTTTTGGGAATGTCAAGAAGTACC (Vocero Akbani
et al., 1996)
5'-TTGCAGACAGCAGACTACAGG 194-210 bp
5'-TTCAGTCTGTGGCTGTCCAG (Vocero Akbani
et al., 1996)
5'-ACTAGGCGACTAATACAGTGGTGC 163 -177 bp
5'-GTGAATTCATCATATGTGATTTCC (Frieje et al., 1992)
Other microsatellites
Details of other primer sequences previously reported are:
D17S925, D17S926, D17S849 (Gyapay et al., 1994); D17S625
(Utah 269) (Gerken et al., 1995); cCII7.713 (Stack et al.,
1994); TP53 (Jones and Nakamura, 1992); cCI17-571,
D17S1147 (Stack et al., 1995).
Multiplex PCR
PCR conditions were as for standard amplifications, with the
exception that two primer sets were used in each reaction.
The test locus copy number (136 bp product, 17TEL primers/
DdeI) was compared with the KRAS2 (196 bp product) locus
copy number. Relative intensity of control and test bands
were compared visually, with reference to products obtained
from DNA isolated from peripheral blood. KRAS2 exon 1
primers were:
F 5'-GCCTGCTGAAAATGACTGAATATA
R 5'-AATGGTCAGAGAAACCTTTATCTG 196 bp
Results
Identification of 17p telomeric polymorphisms
Analysis of the insert/vector junction of the 150 kb YAC,
TYAC98, allowed the identification of a 114 bp STS
(sFJS14). This provided the starting point for marker
isolation. Vectorette libraries were constructed from digested
YAC DNA. Subsequent sequence analysis of a 300 bp17p13.3 loss in malignant disease
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(NlaIV library derived) genomic fragment allowed the design
of a new insert primer. PCR of normal (peripheral blood)
genomic DNA from eight individuals was carried out. To
screen for polymorphisms, direct sequencing of the products
was carried out. To ensure that even poorly informative
markers would be useful, the individuals initially selected
were patients of interest. A Ddel RFLP, detailed in Table I
and Figure 1, was identified.
The sequence was further extended by the design of a new
outward facing primer and a further round of PCR with
vectorette libraries (Haell library gave a clean band of
approximately 300 bp). Sequencing, and subsequent screening
of eight individuals with a newly designed reverse primer
revealed a second polymorphism (C/T). However, in this case
the variation did not alter a restriction site (....TGAG C/T
AGGG....). A primer with a near 3'end mismatch (ending
5'....TGcG 3') was designed. PCR with this primer resulted in
the creation of a Hhal (GcGC or GcGT) RFLP (Table I,
Figure 2). Amplification with Taq DNA polymerase
(Promega) produced surprising results. Subsequent digestion
of heterozygote samples with HhaI suggested that the PCR
had favoured one (cutting) allele in all cases. It was assumed
that this was due to unequal PCR amplification efficiency as
a result ofdiffering degrees of secondary structure, dependent
on the particular base present at the polymorphic site
(primer-binding site adjacent to this base). Using Dynazyme
Table I Details of the two biallelic polymorphisms that combine to give 17TEL
Frequency
AlIlele size For Dde I n =48 Heterozygosity(%
RFLP Primers Sequence Allele (bp) For Hha I n=69 Expected Observed
Dde I 94-649 TCC AGC TAG AAC TTC GTG CA a, 136 0.23 35.4 37.5
95-450 TTC TCC CTT GTT TGG TTG GA a2 92 (+44) 0.77
Hha I 95-448 CCT GTG GGT TTG TCA GCA GT a3 145 0.14 24.1 21.7
95-463 TAA GGT GTC TC.G AGG TGc G a4 126 (+ 19) 0.86
Primer 95-463 has a mismatch one base from the 3' end (lower case).
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(Flowgen) in place of Taq DNA polymerase overcame these
effects. These two linked polymorphisms are subsequently
referred to as 17TEL.
Confirmation of subtelomeric location of 17TEL
Fluorescent in situ hybridisation (FISH) analysis placed the
human sequence carried by TYAC98 distal to all 17pl3.3
YACs tested that encoded known genes or Genethon markers
(Stack et al., 1995). However, there remained a small
possibility that the YAC insert carried a large internal
deletion, and that the 17TEL RFLP markers were derived
from a small proximal component (not seen by FISH).
Multipoint linkage analysis, using the DdeI RFLP and
Genethon markers, placed 17TEL 4.1 cM (sex average, male
7.2 cM, female 1.3 cM, 1000: 1 odds) telomeric from the two
most distal Genethon markers (D17S926 and D17S849) used
in the initial study (Stack et al., 1995). The results suggested
that the RFLP system lay within 150 kb of the 17p telomere.
17p linkage information, including genotypes, will be
available through the WWW Genlink Resource (http://
www.genlink.wustl.edu/).
17TEL LOCH results
Table II details our previous LOH study on 17p and is
reproduced here with the additional 17TEL data. Of the 17
samples heterozygous for 17TEL, 10 (59%) were found to
show loss. In the four cases where the samples were
heterozygous for both polymorphisms, they gave identical
findings. There was a tendency for the telomeric polymorph-
ism to be lost if distal markers were also lost (nine cases, e.g.
661), and retained if distal markers were retained (four cases,
e.g. 518). But there were also three cases where the telomere
was not lost when distal markers were (e.g. 584) and one case
(692) where the telomere was lost and distal markers were
not.
A similar LOH study was conducted using resectable
staged, non-small-cell lung tumours, the results of which are
shown in Table III. Here the pattern of loss is less complex
than in the breast tumours, with 13 out of 18 (72%) showing
loss of all informative markers on the p arm including TP53
(e.g. L61) and four out of 18 (22%) showing no loss of any
informative markers (e.g. L26); this includes case L71 which
has marginal imbalance for 17TEL only. This level of loss is
higher than other reports (Chiba et al., 1990; Hiyama et al.,
1995) perhaps because of differences in tumour source or
sample preparation. Sample L74 shows loss of distal markers
but this does not apparently include TP53. The level of loss
for the more proximal marker D17S925 (one out of 13
informative samples) would not be considered significant and
is what might be expected from a region unlinked to
tumorigenesis. Interestingly, marginal imbalance, often seen
with the breast tumours, was much rarer with the lung
samples. A smaller study was also conducted using Wilms'
tumour and the three distal markers D17S926, D17S695, and
D17S849. Out of 17 paired samples, only two showed loss
and only for one marker (results not shown).
Throughout, we have used the terminology of LOH. But
as this is a PCR-based study, it would be more correct to use
the term allelic imbalance. However, we have some evidence
that the observed imbalances are due to true loss and not
amplification events. A total of 18 DNA samples showing
194-
118-
72-
OX 1T 1N 2T 2N 3T 3N 4T 4N
Figure 1 Ethidium bromide-stained gel showing the DdeI
polymorphism. Tumour DNA is represented as T and normal
DNA (corresponding peripheral blood) is represented as N. The
more common (restricted) allele is 92bp with the uncut 136bp, the
44bp fragment is barely visible. Sample 1 is homozygous cutting
and demonstrates full enzyme digestion. Sample 4 is homozygous
non-cutting, and samples 2 and 3 demonstrate two examples of
LOH in breast cancer (cases 548 and 682 respectively).
194--
118-
72-
OX 5T 5N 6T 6N 7T 7N
Figure 2 Ethidium bromide-stained gel showing the HhaI
polymorphism. Tumour DNA is represented as T and normal
DNA (corresponding peripheral blood) is represented as N. The
more common (restricted) allele is 126bp with the uncut 145bp,
the 19bp fragment is not visible. Sample 5 is homozygous cutting
and demonstrates full enzyme digestion. Sample 7 is homozygous
non-cutting while sample 6 is an example of LOH in breast cancer
(case 88/344).
Tabe I Loss ofheterozygosity study in 18 reectabl, stapd, non-small-veil lung cancer patients
Sample D17S925 TP53 cCIl)7-713 cCI17-571 D17S1174 D17S926 D17S695 D17S849 17TEL
L2 0 - * * - * -
L26 - 0 0
L27 0 - 0 0 0 *
L28 - - - 0 0 0 - * S
L35 0. -0 0 0 0 0 0 -
L61 0 *, - 0
L69 - - - - 0 0 . *
L71 0 0 0 - 0 - 0 -
L72 * - * - * 0 0 0
L74 0 0 0 - * 0 0 0
L76 - * - - 0 0
L77 0 0 0 0 0 0 -
L78 - 0 - 0 0 0 -
L80 0 0 0 * * *
L86 0 0 - 0 0 0 * *
L91 0 0 0 0 0
L95 0 - 0 l * l 0
L100 0 - S .
i os,
, _. ,_ ,., _a . . All markers map t 17pl3 ac 117592 whichi1 t r i *, cla ls - 4 a -los -, non-formaive
samples. Sampleswhere noinformation wasobtainedare leftbnk.Vals forperentage los foreachmarker aregiven atthe foot ofthe table.LOH of 17TEL (lung and breast cancer) were used in
multiplex PCR assays. Although multiplex PCR is not
sufficiently sensitive to measure small differences in starting
target ratios (such as those that might be generated by an
LOH event), large target ratio differences (such as those
created by gene amplification) may be detected with relative
ease (Betticher et al., 1996). Two sets ofprimers (DdeI RFLP,
136 bp and KRAS2, 196 bp) were incorporated in each
reaction. Following PCR, relative band intensity provided a
measure of the relative starting ratios of each locus in the
tumour sample. Gene amplification would result in strength-
ening of the intensity of the band derived from the amplified
gene. In comparison with results from normal control DNA,
no evidence for amplification of 17TEL was obtained in any
tumour sample, suggesting that the allelic imbalance seen at
the telomere reflected true LOH events. Similarly, to exclude
homozygous deletion of the marker, all breast and lung
tumours demonstrating apparent retention of 17TEL (PCR
product may derive from a residual and minority, normal cell
component of the tumour) were analysed by multiplex PCR
(Figure 3). In no case did the data suggest that homozygous
deletion of the region had occurred.
Telomeric imbalance on other chromosomes
To demonstrate that the high level of loss observed at
l7pl3.3 in breast cancer was not a general property of
telomere-associated sequences in tumours, microsatellite
repeat polymorphisms from other chromosome arms were
studied. As a result of the relatively low percentage
heterozygosity of the biallelic polymorphisms, 17TEL data
was available only on a restricted number of cases. It was
decided to increase the number of breast tumours in the
study. Tumours were subsequently divided into two groups,
those showing LOH for 17TEL (17L) and those not showing
LOH (17NL). Table IV shows the telomeric marker and loss
pattern for those breast cancer samples showing LOH for
17TEL. Table V shows the loss pattern for those not showing
LOH for 17TEL. With the small numbers involved,
significant differences were unlikely, but it is clear that no
other telomeric region analysed showed loss at levels higher
than 17p. Indeed, in general, LOH levels were much lower.
There seems to be no great difference between the 17L and
17NL groups suggesting the absence of a subset of tumours
that shed subtelomeric sequences. However, the 17NL group
does appear to show a slightly lower overall level of LOH.
This could perhaps be explained by the unintentional
17p13.3 loss in malignant disease
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Figure 3 Multiplex PCR analysis of tumour and normal DNA
samples. Tumour samples (T, case as numbered) were compared
with corresponding normal DNA (N) from the patients. Tumour
samples 682 and 548 demonstrated allelic imbalance in 17TEL
markers. The multiplex analysis indicated that these imbalances
were not the result of amplification events. Tumour samples 731
and 584 showed no allelic imbalance for 17TEL. The multiplex
suggested that homozygous loss of the 17TEL marker region
(analysed PCR product derived from normal cell component of
tumour) had not occurred. End track is 4X174/HaeIII marker.
selection of some tumours with a high normal component
(10 out of 21 samples showed no loss at any of the markers).
The lung samples were also studied for LOH with the
telomeric markers. The results, as shown in Table VI, were
similar to those obtained for the breast samples with a low
level of loss recorded on other autosomes.
Discussion
We have previously reported evidence for the existence of a
breast cancer-suppressor gene located within the distal region
of 17pl3.3. This study, reporting the identification of a novel
four-allele RFLP system mapped to the 17p subtelomeric
region, extends those initial observations. In almost all cases
examined, the loss region incorporating the distal markers
extends to the telomere. Could we therefore be justified in
ascribing the LOH events observed to simple loss of
subtelomeric sequences in an unstable genome? This
explanation would seem unlikely, given that the levels of
loss at the distal regions of other chromosomes occurred at a
substantially lower frequency. We would therefore argue that
the breast tumour data presented in this study support the
hypothesis that a p53-independent suppressor gene resides
within the subtelomeric region of 17pl3.3.
Although both breast and lung cancers are epithelial in
origin and have known p53 involvement (Prosser et al., 1990;
Mitsudomi et al., 1992), there is a marked difference between
Table IV Results of LOH study using eight microsatellite markers in 16 breast cancer patients that show
17TEL loss
Sample 2p 6q lI p 14q 16q 18q 22q Xq
486 - - 0 - -
548 0 0 0 0 - 0 -
578 0 0 0 - 0 0
591 0 - 0 * - - 0
661 0 0 0 0 0 0 0 0
682 - - 0 - - 0 0
683 0 - 0 0 - 0 - 0
692 0 0 0 0 - 0 0 0
722 0 - _
788 0 0 - 0
88-153 0 0 0 0 0 0 -
88-228 0 0 - 0 0 0 0
88-343 0 0 0 - 0 0 0
88-389 0 0 - 0 - 0
88-397 0 0 - - 0 - 0
89-31 0 -0 0 0 0
89-51 0 0 - - - - 0
Loss/total 2/13 2/7 4/11 5/11 1/4 4/11 2/9 2/12
Loss (%) 15 29 36 45 25 36 22 17
0, loss; 0, no loss; -, non-informative samples. Samples where no information was obtained are left blank.
Values for percentage loss for each marker are given at the foot ofthe table.17pl3.3 loss in malignant disease
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Table V Results of LOH study using eight microsatellite markers in 21
17TEL loss
breast cancer patients that show no
Sample 2p 6q lip 14q 16q 18q 22q Xq
514 O 0 0 0 0 0
518 0 0 0 0 0 0 0
535 - - * - - -
584 - 0 0 * - 0
594 0 0 0
704 00 0 0 0 0
730 0 0 0 0 -0 0 0
731 O 0 0 0 0 0 0 0
640 0 0 0 - 0 0 0
641 0 - 0 0 0 0 0
88-139 0 0 0 0 - 0 - 0
88-226 0 0 0 0 0 0 -
88-361 0 0 0 - 0 0 0
88-19 0 0 0 0 0 0 0 0
89-22 0 - - 0 - 0 0
89-76 0 0 0 0 0 0 0 0
89-86 0 - 0 0 0 0
89-129 O0 0 0 0 0 0
89-139 0 0 0 - 0 0 0
89-163 0 - 0 0 0 0
89-372 0 0 0 0 0 0 0 -
Loss/total 0/18 4/16 2/18 2/17 5/10 2/18 2/15 2/14
Loss (%) 0 25 11 12 50 11 13 14
*, loss; 0, no loss; -, non-informative samples. Samples where no information was obtained are left blank.
Values for percentage loss for each marker are given at the foot ofthe table.
their 17p LOH patterns. Different again were the results for
Wilms' tumour, a paediatric embryonal tumour of the
kidney, in which only very low levels of loss were seen.
Lung tumours generally showed either complete loss or,
alternatively, no loss for all markers on the 17p arm. This
LOH for large regions of chromosome 17 in lung tumours
perhaps shows some similarity to the pattern described in
sporadic ovarian carcinomas, where loss of the entire
chromosome is a very common event (Foulkes et al., 1993).
The LOH pattern for breast cancers was much more
complex, with individual samples showing both loss and no
loss for different markers along the 17p arm. It is interesting
to speculate on the observation that the region of loss on 17p
for lung tumours is so large, possibly including the entire 17p
arm. It is possible that TP53 (or another suppressor) is the
sole target of the LOH events. In this case the large region of
loss could be a result of the particular carcinogenic agents
that lung tissue is exposed to. Alternatively, defects within
two or more separate and distant genes situated on 17p may
be required for tumorigenesis. Possible support for the
existence of multiple 17p suppressor targets is provided by
the observation of LOH at the TP53 locus in lung tumours in
the absence of a detectable mutation in the remaining allele
(Hiyama et al., 1995).
To our knowledge, this is the first major study of the loss
of telomere-associated sequences in malignant disease. The
levels of loss found, in both lung and breast cancer, for the
majority of telomeric markers was, in the main, similar to the
levels considered to be around the borderline for significant
involvement of a region in the development of a tumour type
(10-20%). We are therefore unable to support the idea that
subtelomeric sequences are highly unstable in malignant
disease. Given that telomeres are thought to be required for
chromosome stability, the high level of loss of 17TEL
observed might appear surprising. However, if the loss
mechanism was primarily one of somatic recombination
and reduplication following the LOH event, both 17
homologues would have functional telomeres. Alternatively,
if the LOH events derived from breakage and loss of the
chromosome end, it is possible that telomerase, activated in
the malignant cells, might be involved in re-creation of a
functional telomere at the break site. Telomere capture
(Meltzer et al., 1993) is a further mechanism by which a
chromosome might reacquire a functional terminus.
Table VI Results of LOH study using six microsatellite markers in
18 lung cancer patients
Sample 2p 6q 14q 16q 18q 22q
L2 0 - O - 0 -
L26 0 0 0 - - 0
L27 - 0 0 - 0 0
L28 0 0 - - 0 0
L35 0 0 - 0 0 0
L61 0 0 0 0 0 0
L69 - 0 - - 0 0
L71 0 - 0 0 0 0
L72 - 0 - 0 - 0
L74 - 0 0 0 0
L76 0 - 0 - 0 0
L77 0 0 - - - 0
L78 0 - 0 0 0 -
L80 0 0 0 0 0 0
L86 0 0 0 - 0 0
L91 0 0 - - 0 0
L95 0 0 - 0 0 -
L100 0 0 0 0 -
Loss/total 3/14 2/14 2/10 4/9 4/15 5/14
Loss (%) 21 14 20 44 27 36
0, loss; 0, no loss; -, non-infornative samples. Samples where no
information was obtained are left blank. Values for percentage loss for
each marker are given at the foot ofthe table.
The primary aim of this work was to provide evidence for
the existence of and fine location of, a 17pl3.3-encoded
suppressor gene. Although the region showed very high levels
of loss in lung cancer, strongly supporting the existence of a
17p tumour suppressor, the homogeneity of the deletions and
size of the region involved meant that almost no fine
positional information was derived. In contrast, while still
showing high LOH levels for distal markers, many breast
tumours showed a more heterogeneous 17pl3.3 loss pattern,
from which it might be possible to derive positional
information. However, we are faced with a problem. If we
assume that a single tumour suppressor resides within a
region (as might be the case with an inherited predisposition)
then mapping of a minimal region of deletion (MRD) might
indicate the position of that gene. But if more than one17pl3.3 bu min ut dis_e_
GRM et ix
869
tumour suppressor is present within a region (providing
multiple, potential LOH targets), MRD mapping may lead to
an investigation ofthe wrong area ofthe genome. It might be
possible to overcome this limitation by using very large
numbers of tumours but generally, in the absence of a
familial syndrome and linkage data, we are unable to decide
whether one or multiple targets exist. In addition, a further
layer ofcomplexity is present in PCR-based studies, given the
possibility that areas of homozygous deletion can appear as
regions of retained heterozygosity, through amplification of
the normal cell component ofthe tumour sample (Williamson
et al., 1995). However, we find no evidence for homozygous
deletion at the 17p telomere. Given these limitations and
assuming a single target gene model (which we have no
evidence for) our data would suggest that a breast cancer
tumour suppressor lies between D17S926 and the telomere
(cases 658, 661, 683 and 731). Future assignment of genes
and expressed sequence-tagged sites to this region will allow
us to test this hypothesis.
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